Abstract
HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive metastatic breast cancer, and how to interpret emerging evidence on HER2-low data. They also highlighted best practices for monitoring and managing side effects for patients on these therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
